Wider Losses Might Change The Case For Investing In Viking Therapeutics Stock (VKTX)
- Viking Therapeutics reported third quarter 2026 results with a net loss of US$183.19 million and basic loss per share of US$1.55, and a nine month net loss of US$469.53 million with basic loss per share of US$4.03, both wider than the prior year periods.
- The scale of these higher losses underlines that Viking Therapeutics is still heavily funding obesity and metabolic drug development long before any commercial revenue arrives, which concentrates execution pressure on its clinical programs and cost discipline.
- This raises the question of how Viking Therapeutics' expanding net losses in Q3 2026 might reshape the investment narrative around VK2735.
Viking Therapeutics Investment Narrative Recap
To own Viking Therapeutics, you need to believe its obesity and metabolic pipeline, led by VK2735, can eventually justify years of heavy spending and ongoing losses. The latest Q3 figures, with a wider quarterly and nine month net loss, reinforce that this is still a pure execution story rather than an earnings one.
For near term catalysts, VK2735 late stage data and progress on the oral program remain the key events to watch. The larger losses do not directly change those scientific milestones, but they do sharpen attention on how quickly management can convert high R&D spend into decisive trial readouts and preserve balance sheet flexibility.
The Q3 2026 earnings announcement on October 28 is the clearest recent marker for how Viking Therapeutics is funding that path. A quarterly loss of US$183.19 million, and US$469.53 million over nine months, signals an aggressive push behind obesity and metabolic drug development while the business still reports no revenue.
For you as a shareholder, that report ties directly into the main catalyst and the main risk. Progress of VK2735 through VANQUISH trials and the planned oral Phase III program is what could eventually change the financial profile. Any setback there, combined with continued high spend of this magnitude, would increase pressure for future funding and potential dilution.
Viking Therapeutics' current revenue base is zero, while analysts project revenue of US$118.5 million and earnings of US$12.9 million by 2029. This implies yearly revenue growth from a standing start and an earnings swing of about US$372.5 million from current earnings of a US$359.6 million loss.
Uncover why Viking Therapeutics' fair value indicates a 255% potential upside to its current price, which could narrow quickly if VK2735 data meets expectations.
Exploring Other Perspectives
Some bullish analysts frame the VK2735 oral program as the real swing factor. Before this Q3 2026 loss, they were modeling revenue of about US$1.3b and earnings of roughly US$214.5 million by 2029, far above the consensus US$118.5 million and US$12.9 million. You can treat this spread as an invitation to compare several viewpoints.
Explore 3 other Viking Therapeutics fair value estimates, including one that suggests as much as 265% upside from the current price.
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Viking Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
- See our latest analysis for Viking Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Viking Therapeutics' overall financial health at a glance.
Looking For More Ideas Beyond Viking Therapeutics?
If the Viking Therapeutics story has you thinking more broadly about where to put fresh capital to work, it can help to scan a wider field of opportunities that fit different risk profiles and income needs.
- For investors who want potential mispricing with fundamental support, review our 35 high quality undervalued stocks that combine quality metrics with compressed valuations.
- If capital preservation sits higher on your priority list than aggressive upside, filter for 30 resilient stocks with low risk scores that score well on resilience and financial stability.
- When you want growth potential backed by robust finances rather than hype, shortlist a list of solid balance sheet and fundamentals (23 results) to see which businesses pair sturdy balance sheets with sound fundamentals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com